SEC Filing Summary: Aadi Bioscience, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Aadi Bioscience, Inc. on November 10, 2021. The filing serves to announce the company's financial results for the fiscal quarter ended September 30, 2021. The registrant is an emerging growth company incorporated in Delaware, with its common stock trading on The Nasdaq Stock Market under the symbol AADI.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
No specific material changes versus the prior comparable period are quantified in this filing text. The document solely references the issuance of the press release containing the quarterly results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in Item 2.02 and Item 9.01 (including the press release) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 10, 2021) for actual revenue, net loss, and cash position figures.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol AADI on The Nasdaq Stock Market.
- Note that the financial data in the press release is not deemed "filed" under Section 18 of the Exchange Act.